Soligenix Gets European Union Patent for Synthetic Hypericin as Psoriasis Therapy
News
The European Union has granted Soligenix a patent for its proprietary formulation of synthetic hypericin (SGX301) as a treatment for psoriasis. Synthetic hypericin, the active ingredient in SGX301, is a photosensitizer ... Read more